$0.572
Revenue is down for the last 2 quarters, 124.66K → 114.94K (in $), with an average decrease of 7.8% per quarter
Netprofit is up for the last 2 quarters, -54.46M → -40.64M (in $), with an average increase of 34.0% per quarter
In the last 1 year, Seagen Inc has given 45.9% return, outperforming this stock by 111.9%
In the last 3 years, Moderna Inc has given 23.1% return, outperforming this stock by 119.1%
0.0%
Downside
Day's Volatility :4.98%
Upside
4.98%
2.11%
Downside
52 Weeks Volatility :80.21%
Upside
79.79%
Period | Inovio Pharmaceuticals, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -51.73% | 0.7% | -6.8% |
6 Months | -68.82% | -8.3% | -6.0% |
1 Year | -65.99% | -1.9% | -4.6% |
3 Years | -95.97% | 25.3% | 25.9% |
Market Capitalization | 155.0M |
Book Value | $0.76 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.97 |
PEG Ratio | 0.0 |
Wall Street Target Price | 1.33 |
Profit Margin | 0.0% |
Operating Margin TTM | -2355.96% |
Return On Assets TTM | -42.09% |
Return On Equity TTM | -87.1% |
Revenue TTM | 10.2M |
Revenue Per Share TTM | 0.04 |
Quarterly Revenue Growth YOY | -42.3% |
Gross Profit TTM | -177.4M |
EBITDA | -235.9M |
Diluted Eps TTM | -0.97 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.56 |
EPS Estimate Next Year | -0.38 |
EPS Estimate Current Quarter | -0.14 |
EPS Estimate Next Quarter | -0.14 |
What analysts predicted
Upside of 132.52%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 42.2M | ↑ 19.37% |
Net Income | -88.2M | ↑ 19.62% |
Net Profit Margin | -208.92% | ↓ 0.43% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 30.5M | ↓ 27.8% |
Net Income | -97.0M | ↑ 9.93% |
Net Profit Margin | -318.12% | ↓ 109.2% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 4.1M | ↓ 86.51% |
Net Income | -119.4M | ↑ 23.09% |
Net Profit Margin | -2.9K% | ↓ 2584.63% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 7.4M | ↑ 80.24% |
Net Income | -166.4M | ↑ 39.42% |
Net Profit Margin | -2.2K% | ↑ 657.36% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.8M | ↓ 76.05% |
Net Income | -303.7M | ↑ 82.47% |
Net Profit Margin | -17.1K% | ↓ 14864.48% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 10.3M | ↑ 478.23% |
Net Income | -279.8M | ↓ 7.85% |
Net Profit Margin | -2.7K% | ↑ 14383.2% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 839.1K | ↑ 187.67% |
Net Income | -106.9M | ↑ 77.75% |
Net Profit Margin | -12.7K% | ↑ 7881.89% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 199.1K | ↓ 76.28% |
Net Income | -79.1M | ↓ 26.06% |
Net Profit Margin | -39.7K% | ↓ 26975.49% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 784.4K | ↑ 294.02% |
Net Income | -108.5M | ↑ 37.21% |
Net Profit Margin | -13.8K% | ↑ 25888.8% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 9.2K | ↓ 98.83% |
Net Income | -37.8K | ↓ 99.97% |
Net Profit Margin | -412.75% | ↑ 13419.22% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 124.7K | ↑ 1261.86% |
Net Income | -54.5M | ↑ 144043.77% |
Net Profit Margin | -43.7K% | ↓ 43274.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 114.9K | ↓ 7.8% |
Net Income | -40.6M | ↓ 25.36% |
Net Profit Margin | -35.4K% | ↑ 8322.48% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 187.2M | ↑ 7.79% |
Total Liabilities | 44.8M | ↓ 11.08% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 131.1M | ↓ 29.98% |
Total Liabilities | 44.1M | ↓ 1.5% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 144.0M | ↑ 9.79% |
Total Liabilities | 138.5M | ↑ 214.3% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 539.8M | ↑ 274.97% |
Total Liabilities | 78.6M | ↓ 43.25% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 495.9M | ↓ 8.12% |
Total Liabilities | 96.3M | ↑ 22.43% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 348.5M | ↓ 29.72% |
Total Liabilities | 126.2M | ↑ 31.06% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 495.9M | ↓ 7.43% |
Total Liabilities | 96.3M | ↑ 17.13% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 445.5M | ↓ 10.17% |
Total Liabilities | 90.4M | ↓ 6.07% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 459.4M | ↑ 3.12% |
Total Liabilities | 161.7M | ↑ 78.85% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 392.0M | ↓ 14.68% |
Total Liabilities | 125.3M | ↓ 22.54% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 348.5M | ↓ 11.08% |
Total Liabilities | 126.2M | ↑ 0.72% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 266.6M | ↓ 23.51% |
Total Liabilities | 67.4M | ↓ 46.6% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -63.2M | ↑ 1.05% |
Investing Cash Flow | -27.8M | ↓ 271.04% |
Financing Cash Flow | 95.7M | ↑ 1128.85% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -73.6M | ↑ 16.36% |
Investing Cash Flow | 42.4M | ↓ 252.42% |
Financing Cash Flow | 31.0M | ↓ 67.56% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -97.9M | ↑ 33.04% |
Investing Cash Flow | -9.0M | ↓ 121.32% |
Financing Cash Flow | 105.4M | ↑ 239.58% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -178.0M | ↑ 81.89% |
Investing Cash Flow | -58.8M | ↑ 550.04% |
Financing Cash Flow | 465.3M | ↑ 341.45% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -215.7M | ↑ 21.2% |
Investing Cash Flow | -175.3M | ↑ 198.23% |
Financing Cash Flow | 211.5M | ↓ 54.54% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -216.2M | ↑ 0.23% |
Investing Cash Flow | 109.6M | ↓ 162.5% |
Financing Cash Flow | 81.8M | ↓ 61.3% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -37.9M | ↓ 18.5% |
Investing Cash Flow | -6.5M | ↓ 111.61% |
Financing Cash Flow | 47.6M | ↓ 10897.89% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -61.9M | ↑ 63.32% |
Investing Cash Flow | 21.3M | ↓ 428.49% |
Financing Cash Flow | 28.4M | ↓ 40.28% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -50.5M | ↓ 18.35% |
Investing Cash Flow | -10.3M | ↓ 148.3% |
Financing Cash Flow | 42.9M | ↑ 51.08% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -118.0M | ↑ 133.52% |
Investing Cash Flow | 44.6M | ↓ 532.42% |
Financing Cash Flow | 46.8M | ↑ 8.88% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -36.3M | ↓ 69.2% |
Investing Cash Flow | 54.0M | ↑ 21.2% |
Financing Cash Flow | 6.7M | ↓ 85.74% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -36.7M | ↑ 0.89% |
Investing Cash Flow | 19.0M | ↓ 64.82% |
Financing Cash Flow | -424.7K | ↓ 106.37% |
Sell
Neutral
Buy
Inovio Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Inovio Pharmaceuticals, Inc. | -21.41% | -68.82% | -65.99% | -95.97% | -87.13% |
![]() Moderna, Inc. | -4.27% | -29.63% | -10.94% | 105.39% | 586.61% |
![]() Regeneron Pharmaceuticals, Inc. | -8.82% | -3.37% | 11.63% | 22.7% | 139.69% |
![]() Seagen, Inc. | -1.74% | 61.71% | 45.87% | 23.07% | 217.59% |
![]() Vertex Pharmaceuticals Incorporated | -6.21% | 0.88% | 20.1% | 12.88% | 112.8% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Inovio Pharmaceuticals, Inc. | NA | NA | 0.0 | -0.56 | -0.87 | -0.42 | 0.0 | 0.76 |
![]() Moderna, Inc. | 11.46 | 11.46 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.72 | 19.72 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.15 | 26.15 | 0.41 | 14.62 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Inovio Pharmaceuticals, Inc. | Sell | $155.0M | -87.13% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $49.1B | 586.61% | 11.46 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $79.5B | 139.69% | 19.72 | 33.81% |
![]() Seagen, Inc. | Hold | $36.7B | 217.59% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $83.8B | 112.8% | 26.15 | 35.4% |
State Street Corporation
BlackRock Inc
Vanguard Group Inc
D. E. Shaw & Co LP
Geode Capital Management, LLC
Millennium Management LLC
Inovio Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None
Read MoreINOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. INOVIO's lead immunotherapy candidate, VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, cleared high-risk HPV-16 and/or HPV-18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as infectious disease DNA vaccine development programs in coronaviruses associated with COVID-19 diseases and MERS, Lassa fever, Ebola, and HIV. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards 'W' designation recognizing companies with more than 20% women on their board of directors.
Organization | Inovio Pharmaceuticals, Inc. |
Employees | 184 |
CEO | Dr. Jacqueline E. Shea Ph.D. |
Industry | Health Technology |